NCT04098029 (CP-HLA2019) is a Phase 2 clinical trial of Low HLA group CBU infusion in Cerebral Palsy, sponsored by State-Financed Health Facility "Samara Regional Medical Center Dinasty".

Who is sponsoring NCT04098029?

NCT04098029 is sponsored by State-Financed Health Facility "Samara Regional Medical Center Dinasty".

What drugs are being tested in NCT04098029?

Interventions in NCT04098029: Low HLA group CBU infusion, High HLA group CBU infusion, Standard therapy.

What condition does NCT04098029 study?

NCT04098029 studies Cerebral Palsy.

Is NCT04098029 still recruiting?

NCT04098029 is currently status unknown. Last updated 18 January 2023.

Last reviewed 2023-01-18 · How we verify

NCT04098029: CP-HLA2019

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Estimation of the Safety and Efficiency Transfusion of HLA Matched CBU in Patients With CP

Status unknown Phase 2 Last updated 18 January 2023

What this trial tests

Phase 2 trial testing Low HLA group CBU infusion in Cerebral Palsy in 150 participants. Status unknown.

Timeline

1 September 2019

Primary endpoint
26 December 2023

26 May 2024

Quick facts

Lead sponsor	State-Financed Health Facility "Samara Regional Medical Center Dinasty"
Phase	Phase 2
Status	Status unknown
Study type	INTERVENTIONAL
Allocation	non randomized
Design	parallel
Masking	none
Primary purpose	treatment
Enrollment	150
Start date	1 September 2019
Primary completion	26 December 2023
Estimated completion	26 May 2024
Sites	1 location across Russia

Drugs / interventions tested

Low HLA group CBU infusion — full drug profile →
High HLA group CBU infusion — full drug profile →
Standard therapy — full drug profile →

Conditions studied

Cerebral Palsy — all drugs for Cerebral Palsy →

Sponsor

State-Financed Health Facility "Samara Regional Medical Center Dinasty"

Who can join

Adults 1 to 12, any sex, with Cerebral Palsy. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Cerebral palsy is a disorder of movement and posture resulted from a non-progressive lesion or injury of the immature brain. It is a leading cause of childhood-onset disability. Many experimental animal studies have revealed that umbilical cord blood is useful to repair neurological injury in the brain. Based on many experimental studies, umbilical cord blood is suggested as a potential therapy for cerebral palsy. This protocol was developed based on the results of the previously approved protocol of the center NCT03826498 (Allogeneic cord blood transfusion in patients with infantile cerebral palsy), which showed high efficiency in the rehabilitation of patients. The present protocol is intended for revealing the dependence of the clinical effect on the degree of tissue compatibility of umbilical cord blood samples and the recipient

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

Progress in clinical trials of stem cell therapy for cerebral palsy.
Lv ZY, Li Y, Liu J. · · 2021 · cited 29× · PMID 33318421 · DOI 10.4103/1673-5374.300979

Verify or expand the search:

Other recruiting trials for Cerebral Palsy

Currently open trials in the same condition.

NCT07524972 — Antenatal Magnesium Sulphate in High-Risk Preterm Patients · Phase 3 · recruiting
NCT07432789 — Metrological Properties of a Digital Motion Analysis Research Application for Assessing the Motor Abilities and Performa · NA · recruiting
NCT07466914 — Constipation in Children With Cerebral Palsy · active not recruiting
NCT05901259 — The EXOPULSE Study - a Database for Routine Follow-up of Clinical Outcomes · recruiting
NCT07342348 — Using Power Mobility Training to Promote Arm & Hand Function in Children With Cerebral Palsy · NA · recruiting

Other State-Financed Health Facility "Samara Regional Medical Center Dinasty" trials

Trials by the same sponsor.

NCT04491240 — Evaluation of Safety and Efficiency of Method of Exosome Inhalation in SARS-CoV-2 Associated Pneumonia. · Phase 1, PHASE2 · completed
NCT04099381 — Safety and Efficacy of the Transfusion of UCB in Patients With an ASD Depending on the Degree of HLA Compatibility. · Phase 1, PHASE2 · unknown
NCT03786744 — Allogenic Cord Blood Transfusion in Patients With Autism · Phase 1, PHASE2 · completed
NCT03762967 — Autologous Adipose-Derived Adult Stromal Vascular Cell Administration for Male Patients With Infertility · Phase 2 · unknown
NCT03826498 — Allogenic Cord Blood Transfusion in Patients With Cerebral Palsy · Phase 2 · unknown

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT04098029 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by State-Financed Health Facility "Samara Regional Medical Center Dinasty"
Last refreshed: 18 January 2023

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04098029.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing